Indian pharmaceutical firm Sun Pharmaceutical must double its current offer for the remaining stake in Taro if it is to be successful.
Sun currently owns 66% of the company and has offered to acquire the remaining 34% at $24.5 a share, equivalent to a 26% premium over its $19.45 trade price on Monday.
Go deeper with GlobalData
This bid was, however, rejected by one of the remaining shareholders, Grand Slam Asset Management, which has requested almost double that amount.
Grand Slam has stated it believes a fair evaluation would be at least 15 times the company’s EBITDA, corresponding with six similar acquisitions of US generic drug manufacturers, equivalent to $48.5 a share.
Grand Slam reiterated its stance in a letter to the Taro board, which also urged the hire of independent counsel and investment bankers in order to oversee any further Sun offers.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
